News of Note—GlaxoSmithKline in Nigeria; Mexico fights shortages

Financial market data. Image: Pixabay

> GlaxoSmithKline Consumer Nigeria has selected Nigeria's Fidson Healthcare to manufacture five formations of its respiratory and wellness products for the Nigerian market. Story

> Lupin has received a notice from the FDA that an inspection of its plant in Goa resulted in a finding of Official Action Indicated. Story

> The Mexican government has pledged to fix drug shortages at hospitals that have been blamed on a government plan aimed at cutting costs. Story

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> The FDA's Office of Pharmaceutical Quality has issued a report on strides made to improve the global drug supply that comes into the U.S. Report (PDF)

> Fujifilm Diosynth Biotechnologies is investing £3.6 million to build a new facility at its site in the U.K., the first phase of a £12.6 million expansion project. Story

> According to a new report from CPhI, the Middle East currently imports about 90% of its medicines and is ripe for expansion for local manufacturing. Report

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.